不圆 发自 凹非寺 量子位 | 公众号 QbitAI Thinking模式当道，教师模型也该学会" 启发式 "教学了—— 由Transformer作者之一Llion Jones创立的明星AI公司 Sakana AI ，带着他们的新方法来了！ 这个方法要求教师模型像优秀的人类教师一样，根据已知解决方案输出清晰的逐步解释，而不再是从头开始自己解决。 用Sanaka AI的新方法训练出的7B小模型，在传授推理技能方面，比671B的DeepSeek-R1还要有效。 | Teacher | Student | | | Final model AIME 2024 MATH 500 GPQA Diamond Overall | | | | --- | --- | --- | --- | --- | --- | --- | | N.A. | | Owen-7B | 10.00 | 74.20 | 33.30 | 39.17 | | DeepSeek-R1 (671B) Qwen-7B | | Bespoke-7B | 20.00 | 82.00 | 37.80 | 46.60 | | RLT teacher (7B) | | ...

2025年1月，Immunome完成1.5亿美元融资，此轮融资将推动核心管线的临床转化。3月，Immunome宣布靶向ROR1的ADC（抗体-偶联药物）IM-1021完 成I期临床试验首例患者给药。其核心产品管线Varegacestat（AL102）Ⅲ期RINGSIDE试验也已完成入组，预计2025年下半年公布顶线数据。 Immunome的核心竞争力是快速抗体筛选与精准递送技术。高效、精准且安全性高的治疗优势突破了传统癌症治疗中"脱靶损伤"与研发周期过长的行业瓶 颈。 这家临床阶段的靶向肿瘤学公司已累计融资5.989亿美元、21轮资本加持——成立17年的Immunome，凭什么让投资者持续买单？ 利用天然抗体解决脱靶损伤的精准性难题 传统化疗与放疗的局限性在于其作用机制缺乏特异性，药物或辐射在攻击癌细胞的同时会无差别损伤快速分裂的健康细胞（如骨髓、消化道细胞），导致 患者免疫力下降、脱发等严重副作用。这种攻击对人体健康组织损伤率高达60%。以胰腺癌为例，传统放疗虽能缩小肿瘤，但患者容易出现消化道溃疡等 严重并发症。 据塔夫茨药物开发研究中心数据，开发一款新药平均耗时10年、耗资26亿美元左右，且90%以上候选 ...

Core Insights - Marriott International is focusing on budget travelers who prioritize travel but seek more affordable options, as indicated by spending data from credit card relationships [1][5] - The company has significantly expanded into the mid-scale segment, which it historically did not operate in, starting with the acquisition of City Express for $100 million in 2022 [2][5] - Marriott has launched its first StudioRes in Fort Myers, Florida, targeting cost-conscious consumers with modest services and amenities [3] Financial Performance - In the first quarter, Marriott generated $6.26 billion in revenue and reported a net income of $665 million [4] Strategic Initiatives - The introduction of StudioRes aims to cater to various travel purposes, appealing to individuals on temporary assignments or digital nomads [3] - Marriott's diverse portfolio includes brands like Ritz-Carlton, St. Regis, Sheraton, Courtyard, Westin, and Moxy, allowing the company to offer suitable accommodations for different consumer needs [3]

Core Insights - American Oncology Network (AON) is expanding access to radioligand therapies (RLT) for prostate and neuroendocrine cancers, reflecting a commitment to innovative cancer care [1][5] - Over 300 treatments have been administered to nearly 70 patients across five AON partner practices, indicating strong demand and success for these therapies [1][5] Company Overview - AON is a rapidly growing community oncology network founded in 2018, representing over 290 providers across 21 states [6] - The organization focuses on value-based care, improving patient outcomes while reducing costs and expanding access to quality care [6] - AON aims to promote health equity by addressing disparities in cancer care and ensuring all patients have access to necessary treatments [6] Radioligand Therapies - AON now offers three FDA-approved radiopharmaceuticals: Pluvicto™, Xofigo, and Lutathera, targeting specific cancer types [2][3] - Radioligand therapy involves attaching a radioactive isotope to a targeting molecule, allowing for precise radiation delivery to cancer cells while minimizing damage to healthy tissue [2][3] Future Growth - AON anticipates continued growth in the utilization of radioligand therapies as more sites obtain the necessary infrastructure and regulatory approvals [5]

Financial Data and Key Metrics Changes - Comparable hotel total RevPAR increased by 2.1% over 2023, driven by growth in food and beverage revenues and ancillary spending [14] - The company ended the year with $2.3 billion of total available liquidity, including $1.5 billion under its credit facility, and returned $844 million to stockholders through dividends and share repurchases [15][18] - The company invested nearly $550 million in capital expenditures in 2024 [15][17] Business Line Data and Key Metrics Changes - The acquisition of the Ritz Carlton Oahu Turtle Bay in 2024 expanded the company's presence in Hawaii, contributing to future growth expectations [10][11] - The company completed renovations to approximately 2,100 guest rooms and 213,000 square feet of meeting space in 2024 [17] Market Data and Key Metrics Changes - A slower recovery in Maui and moderating domestic leisure demand impacted RevPAR growth in 2024, with total RevPAR growing faster than RevPAR driven by room spending [16] Company Strategy and Development Direction - The company focuses on disciplined capital allocation, including acquisitions, reinvestment in the portfolio, share repurchases, and dividends [12][14] - The company maintains a strong investment-grade balance sheet, with 99% of its portfolio unencumbered by debt, providing flexibility for future investments [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for 2025 and beyond, despite heightened uncertainty in the macroeconomic environment [20] - The company believes its diversified portfolio and strong balance sheet will support performance in the coming years [20] Other Important Information - The company was recognized as a global leader in corporate responsibility, being included in the Dow Jones Best in Class World Index for the sixth consecutive year [19] Q&A Session Summary - No questions were received during the Q&A period, and all proposals, including the election of directors and the appointment of KPMG as auditors, were approved [22][23]